Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate if tocolysis with atosiban in late preterm birth (30
to 34 weeks) is (cost-) effective compared with placebo in improving neonatal morbidity and
mortality.
Phase:
Phase 4
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators:
Amphia Hospital Deventer Ziekenhuis Diakonessenhuis, Utrecht Erasmus Medical Center Flevoziekenhuis Franciscus Gasthuis Gelre Hospitals Groene Hart Ziekenhuis Haaglanden Medical Centre Isala Leiden University Medical Center Maastricht University Medical Center Martini Hospital Groningen Maxima Medical Center Medical Centre Leeuwarden Medisch Spectrum Twente National Maternity Hospital, Ireland Nottingham University Hospitals NHS Trust OLVG Radboud University Medical Center Rijnstate Hospital Spaarne Gasthuis ST. Antonius hospital Nieuwegein Tergooi Hospital UMC Utrecht University Medical Center Groningen Ziekenhuisgroep Twente ZonMw: The Netherlands Organisation for Health Research and Development Zuyderland Medical Centre